JP2024535871A - アルツハイマー病による認知症を有する患者をｔｈｃとメラトニンとの組合せで処置するための組成物および方法 - Google Patents

アルツハイマー病による認知症を有する患者をｔｈｃとメラトニンとの組合せで処置するための組成物および方法 Download PDF

Info

Publication number
JP2024535871A
JP2024535871A JP2024517078A JP2024517078A JP2024535871A JP 2024535871 A JP2024535871 A JP 2024535871A JP 2024517078 A JP2024517078 A JP 2024517078A JP 2024517078 A JP2024517078 A JP 2024517078A JP 2024535871 A JP2024535871 A JP 2024535871A
Authority
JP
Japan
Prior art keywords
thc
compound
medicament
compounds
melatonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024517078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535871A5 (https=
Inventor
ムクンダ，ラーマチャンドラ
ラオ，ジャガディッシュ，エス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGC Pharma IP LLC
Original Assignee
IGC Pharma IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IGC Pharma IP LLC filed Critical IGC Pharma IP LLC
Publication of JP2024535871A publication Critical patent/JP2024535871A/ja
Publication of JP2024535871A5 publication Critical patent/JP2024535871A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2024517078A 2021-09-17 2022-09-16 アルツハイマー病による認知症を有する患者をｔｈｃとメラトニンとの組合せで処置するための組成物および方法 Pending JP2024535871A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163245799P 2021-09-17 2021-09-17
US63/245,799 2021-09-17
PCT/US2022/076579 WO2023044433A1 (en) 2021-09-17 2022-09-16 Compositions and methods for treating patients with dementia due to alzheimer's disease with a combination of thc and melatonin

Publications (2)

Publication Number Publication Date
JP2024535871A true JP2024535871A (ja) 2024-10-02
JP2024535871A5 JP2024535871A5 (https=) 2025-09-25

Family

ID=83688895

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517078A Pending JP2024535871A (ja) 2021-09-17 2022-09-16 アルツハイマー病による認知症を有する患者をｔｈｃとメラトニンとの組合せで処置するための組成物および方法

Country Status (8)

Country Link
US (1) US20250275935A1 (https=)
EP (1) EP4401717A1 (https=)
JP (1) JP2024535871A (https=)
CA (1) CA3232209A1 (https=)
CL (1) CL2024000782A1 (https=)
CO (1) CO2024004628A2 (https=)
PE (1) PE20241236A1 (https=)
WO (1) WO2023044433A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773527A4 (en) 2018-03-30 2022-04-13 India Globalization Capital, Inc. METHOD AND COMPOSITION FOR THE TREATMENT OF CNS DISEASES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR44305E (fr) 1933-12-09 1934-12-24 Meaf Mach En Apparaten Fab Nv Circuits de voie à rails sans potentiel ou portés au même potentiel
US11065225B1 (en) 2015-07-30 2021-07-20 University Of South Florida Ultra-low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's disease
EP3538122B1 (en) * 2016-11-14 2025-03-26 Farm To Farma, Inc. Cannabinoid formulations and method of making the same
EP3582755A4 (en) * 2017-02-15 2020-12-23 Molecular Infusions, LLC PREPARATIONS
WO2019036243A1 (en) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations
US20200246404A1 (en) * 2017-02-15 2020-08-06 Molecular Infusions, Llc Formulations
EP3773527A4 (en) 2018-03-30 2022-04-13 India Globalization Capital, Inc. METHOD AND COMPOSITION FOR THE TREATMENT OF CNS DISEASES
WO2021011421A1 (en) * 2019-07-12 2021-01-21 University Of South Florida Compositions and methods for treating alzheimers disease

Also Published As

Publication number Publication date
WO2023044433A1 (en) 2023-03-23
PE20241236A1 (es) 2024-06-19
CO2024004628A2 (es) 2024-05-10
US20250275935A1 (en) 2025-09-04
CA3232209A1 (en) 2023-03-23
EP4401717A1 (en) 2024-07-24
CL2024000782A1 (es) 2024-09-23

Similar Documents

Publication Publication Date Title
US10052339B2 (en) Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
US10117883B2 (en) Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
JP2023001138A (ja) 新規カンナビノイド組成物および使用方法
WO2018011808A1 (en) Self-emulsifying compositions of cannabinoids
AU2016322148A1 (en) Cannabinoid-containing oral pharmaceutical composition, method for preparing and using same
AU2015292915A1 (en) Solid dosage form composition for buccal or sublingual administration of cannabinoids
US20140243422A1 (en) Methods of treating behavioral and psychiatric disorders
US9655910B2 (en) Compositions and methods for treating addiction
EP2849770A1 (en) Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
CA2867891A1 (en) App specific bace inhibitors (asbis) and uses thereof
EP3773527A1 (en) Method and composition for treating cns disorders
US20180228731A1 (en) Polyphenolic polymer to make water-insoluble molecules become water-soluble
Yasamineh et al. Potential use of the cholesterol transfer inhibitor U18666A as a potent research tool for the study of cholesterol mechanisms in neurodegenerative disorders
JP2024535871A (ja) アルツハイマー病による認知症を有する患者をｔｈｃとメラトニンとの組合せで処置するための組成物および方法
CN102552135A (zh) 制备维生素k1乳剂的方法和维生素k1乳剂
US20200268684A1 (en) Composition for treating and preventing neurological diseases, neuroinflamation and alzheimer's disease
CN121443298A (zh) 用于治疗持续性脑震荡后症状的苯加兰他敏
WO2016099944A1 (en) Use of ellagic acid dihydrate in pharmaceutical formulations to regulate blood glucose levels
Yuan et al. Baicalein Long‐Circulating Liposomes Improve Histological and Functional Outcomes After Traumatic Brain Injury
Srivastav et al. An investigation into Alzheimer's disease, its current treatments, biomarkers, and risk factors
WO2022027053A1 (en) Micelle preparations of full-spectrum hemp oil for treating type ii diabetes, reducing inflammation during covid-19, and improving sleep quality
US12011470B2 (en) Micelle preparations of full-spectrum hemp oil
WO2020188569A1 (en) Methods and compositions for preventing or treating weight gain caused by psychiatric drugs
US20220031635A1 (en) Treating COVID 19 by using a mixture of cannabinoids in micellized form to lower levels of pro-inflammatory cytokines and reduce risk of cytokine storm
US20200108082A1 (en) Methods and compositions for treating diseases related to imbalance of essential fatty acids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250916